Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Total Liabilities
Everything the company owes to creditors and other parties.
Opus Genetics, Inc.NASDAQ: IRD
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 161.3% from a year ago
Total liabilities stood at $112.62M at the end of Q1 FY2026, up 161.3% from a year earlier and up 222.7% from the prior quarter. Over 3 fiscal years it compounded at +133.2% a year.
Context
- Total liabilities amounted to 168.6% of total assets at the end of Q1 FY2026, up 79.2 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +161.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 34.9M USD
- Year-over-year change
- +15.8%
- 4-year CAGR
- +73.5%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.9M | +15.8% |
| FY2024 | 2024-12-31 | 30.14M | +645.6% |
| FY2023 | 2023-12-31 | 4.04M | +46.8% |
| FY2022 | 2022-12-31 | 2.75M | -28.6% |
| FY2021 | 2021-12-31 | 3.86M | — |
Total Liabilities vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 total liabilities of $112.62M is the 3rd highest of the 10 companies compared; the peer median is $46.15M.
- Its year-over-year change of +161.3% is the highest of 10, against a peer median of -15.5%.
- Total liabilities amounts to 168.6% of total assets for IRD, versus a peer median of 44.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $414.44M | -20.7% | +2.5% | 222.3% | |
| Mar 2026 | $229.53M | -26.8% | -22.9% | 95.7% | |
IRDOpus Genetics, Inc. | Mar 2026 | $112.62M | +161.3% | +133.2% | 168.6% |
| Mar 2026 | $91.12M | -19.9% | -34.7% | 77.5% | |
| Mar 2026 | $89.73M | -3.0% | -8.9% | 44.8% | |
| Mar 2026 | $46.15M | -5.7% | +88.6% | 34.5% | |
| Mar 2026 | $43.71M | +21.3% | -26.4% | 87.8% | |
| Mar 2026 | $30.65M | -15.5% | -3.5% | 11.3% | |
| Mar 2026 | $6.51M | +36.2% | +30.4% | 21.9% | |
| Mar 2026 | $6.23M | -44.5% | +11.5% | 17.2% | |
| Peer median (excluding IRD) | $46.15M | -15.5% | -3.5% | 44.8% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.